Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NSCLC Market Snapshot: Promising Biomarkers, Testing Challenges

Executive Summary

Biomarker-guided targeted therapy has become a standard approach to oncology R&D, but few new targeted drugs have reached the market for lung cancer. A new wave of research could change that, and improve the outlook for lung cancer treatment.

Related Content

Can Wealth Of Molecular Data Enable Promise Of Chemoprevention?
Pfizer’s Crizotinib Eases Past FDA With Targeted Population
FDA’s NSCLC Guidance Stresses Overall Survival Endpoint, Sets PFS Standards
Market Snapshot: Taking Constipation Seriously – Linaclotide Success Raises Hopes For Market Resurgence
COX-2 Inhibitors No Longer The Pits: Tragara's Apricoxib Shows Potential In Phase II APRICOT-L Lung Cancer Trial
Preparing For A Pricing Shift: Roche Admits Cost Is An Issue In Oncology And Beyond
Survival Data For Pfizer's Crizotinib Appears Promising, Positioning It For Accelerated Approval
Cancer Drugs Have The Worst Phase III Track Record, BIO Study Shows
Tarceva Could Lock Down Market For First-Line Non-Small Cell Lung Cancer With EGFR Mutation
For Nexavar In Lung Cancer, Focus Moves From First To Second Line





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts